
Adam Craig, CTI BioPharma CEO
A new JAK inhibitor earns FDA nod in myelofibrosis, setting up a fight with Incyte, Bristol Myers
The FDA on Tuesday handed down an accelerated approval for CTI BioPharma’s JAK inhibitor Vonjo (pacritinib) to treat intermediate or high-risk primary or secondary myelofibrosis …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.